Cell and Gene Therapies, Biosimilars, Medical Benefit Drugs Are Areas to Watch Moving Forward
While the FDA approved a large number of specialty drugs in 2023, payers shouldn’t let their attention wander in 2024. Multiple potential blockbusters are slated for decisions by the agency this year, as are several biosimilars and generic versions of specialty medications. Gene therapies will continue to garner headlines — and payer dollars. All of these trends and more point to an active year ahead within the specialty pharmacy space. AIS Health, a division of MMIT, spoke with some industry experts about what’s on board.
AIS Health: What are some specialty pharmacy issues to keep an eye on in 2024, and why?
© 2025 MMIT
Related Posts
January
11
2023 Notable FDA Approvals Include Several Cell and Gene Therapies, First-Time Biosimilars
READ MORE
February
9
2023 Outlook: Humira Is Not Only Specialty Drug With Anticipated Biosimilars
READ MORE
February
9